Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Receives Compelling Data From Texas Tech University On Its Herceptin(R) BT2111 Program

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 11, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that research underway at Texas Tech University Health Sciences...
May 31, 2012 19:58 ET | Source: biOasis Technologies Inc.

biOasis Announces Grant of Stock Options to IR Providers

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 31, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces that subject to regulatory approval it will grant additional options in...
May 08, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Transcend Vector Delivers an Anti-Amyloid Beta (AB) Antibody To The Brain

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 8, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) today announces test results from its Transcend therapeutic development program...
April 23, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Closes Private Placement for $2,484,000 Gross Proceeds

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 23, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) (the "Company") is pleased to announce it has closed its non-brokered private...
April 11, 2012 18:59 ET | Source: biOasis Technologies Inc.

biOasis Announces Non-Brokered Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 11, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) (the "Company") is pleased to announce a non-brokered private placement of up to...
March 13, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis' BT2111-Herceptin(R) Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity Assay

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 13, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) today announces positive test results from its Transcend therapeutic BT2111 development...
February 15, 2012 10:10 ET | Source: biOasis Technologies Inc.

biOasis Named to TSX Venture Top 50(R)

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 15, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces it has been named one of the 2012 TSX Venture Top 50® companies. The...
January 30, 2012 09:00 ET | Source: biOasis Technologies Inc.

biOasis Advances its Herceptin(R) BT2111 Program

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that work is underway at Texas Tech University Health Sciences...
January 16, 2012 20:14 ET | Source: biOasis Technologies Inc.

biOasis Enters Investor Relations Agreement With Brisco Capital Partners Corp.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 16, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) (the "Company") is pleased to announce that it has Brisco Capital Partners Corp....
November 30, 2011 18:47 ET | Source: biOasis Technologies Inc.

biOasis Announces Closing of Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 30, 2011) - biOasis Technologies Inc. (TSX VENTURE:BTI) (the "Company") is pleased to announce that it has closed its private placement...